CN1214011C - 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物 - Google Patents

作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物 Download PDF

Info

Publication number
CN1214011C
CN1214011C CNB998035815A CN99803581A CN1214011C CN 1214011 C CN1214011 C CN 1214011C CN B998035815 A CNB998035815 A CN B998035815A CN 99803581 A CN99803581 A CN 99803581A CN 1214011 C CN1214011 C CN 1214011C
Authority
CN
China
Prior art keywords
compound
solution
add
preparation
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998035815A
Other languages
English (en)
Chinese (zh)
Other versions
CN1291978A (zh
Inventor
T·E·罗格斯
P·G·鲁敏斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of CN1291978A publication Critical patent/CN1291978A/zh
Application granted granted Critical
Publication of CN1214011C publication Critical patent/CN1214011C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
CNB998035815A 1998-03-04 1999-02-22 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物 Expired - Fee Related CN1214011C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04
US09/034,270 1998-03-04

Publications (2)

Publication Number Publication Date
CN1291978A CN1291978A (zh) 2001-04-18
CN1214011C true CN1214011C (zh) 2005-08-10

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998035815A Expired - Fee Related CN1214011C (zh) 1998-03-04 1999-02-22 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物

Country Status (29)

Country Link
EP (1) EP1060164A1 (ja)
JP (1) JP2002505323A (ja)
KR (1) KR20010041584A (ja)
CN (1) CN1214011C (ja)
AP (1) AP1244A (ja)
AR (1) AR018139A1 (ja)
AU (1) AU753230B2 (ja)
BG (1) BG104740A (ja)
BR (1) BR9908470A (ja)
CA (1) CA2322207A1 (ja)
EA (1) EA200000804A1 (ja)
EE (1) EE200000506A (ja)
GE (1) GEP20033118B (ja)
HR (1) HRP20000574A2 (ja)
HU (1) HUP0100865A3 (ja)
ID (1) ID25591A (ja)
IL (1) IL137653A0 (ja)
IS (1) IS5582A (ja)
MY (1) MY123908A (ja)
NO (1) NO315703B1 (ja)
NZ (1) NZ506598A (ja)
OA (1) OA11530A (ja)
PL (1) PL342726A1 (ja)
SK (1) SK13002000A3 (ja)
TR (1) TR200002542T2 (ja)
UA (1) UA71906C2 (ja)
WO (1) WO1999044994A1 (ja)
YU (1) YU52000A (ja)
ZA (1) ZA994406B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
CA2510050A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
EP2131861A2 (en) 2007-03-01 2009-12-16 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US9856201B2 (en) * 2014-06-04 2018-01-02 Monsanto Technology Llc 3,6-dichlorosalicylic acid compounds and related synthetic processes
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
MX2022014200A (es) 2020-05-14 2022-12-07 Ube Corp Derivado de 1,4,5,6-tetrahidropirimidin-2-amina.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
JPWO2023085396A1 (ja) 2021-11-12 2023-05-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203234T1 (de) * 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten

Also Published As

Publication number Publication date
NO20004316L (no) 2000-11-06
WO1999044994A1 (en) 1999-09-10
IS5582A (is) 2000-08-04
MY123908A (en) 2006-06-30
BR9908470A (pt) 2000-12-05
YU52000A (sh) 2003-02-28
EE200000506A (et) 2002-04-15
CA2322207A1 (en) 1999-09-10
IL137653A0 (en) 2001-10-31
BG104740A (en) 2001-02-28
AU3294799A (en) 1999-09-20
HUP0100865A2 (hu) 2001-08-28
AR018139A1 (es) 2001-10-31
HUP0100865A3 (en) 2001-11-28
ZA994406B (en) 2000-02-11
JP2002505323A (ja) 2002-02-19
KR20010041584A (ko) 2001-05-25
AP1244A (en) 2004-02-04
HRP20000574A2 (en) 2001-08-31
PL342726A1 (en) 2001-07-02
CN1291978A (zh) 2001-04-18
NO20004316D0 (no) 2000-08-30
OA11530A (en) 2004-05-17
ID25591A (id) 2000-10-19
TR200002542T2 (tr) 2001-05-21
EP1060164A1 (en) 2000-12-20
SK13002000A3 (sk) 2001-07-10
NO315703B1 (no) 2003-10-13
GEP20033118B (en) 2003-11-25
EA200000804A1 (ru) 2001-04-23
AP2000001893A0 (en) 2000-09-30
NZ506598A (en) 2003-07-25
UA71906C2 (en) 2005-01-17
AU753230B2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
CN1214011C (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1207288C (zh) 逆病毒蛋白酶抑制化合物
CN1097051C (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1043997C (zh) 2,6-二氨基嘌呤衍生物及其用途和含该衍生物的药物组合物
CN1083452C (zh) 抑制蛋白质酪氨酸激酶介导的细胞增殖的吡啶并[2,3－d]嘧啶
CN1045768C (zh) 一种血管紧张肽ⅱ拮抗剂化合物及其制备方法和用途
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1154494C (zh) 腺苷a3受体调节剂
CN1218943C (zh) 4－嘧啶基－n－酰基－l－苯基丙氨酸类化合物
CN1304406A (zh) 作为玻连蛋白拮抗剂的杂环甘氨酰β－丙氨酸衍生物
CN1314682C (zh) 抑制由α4整合素调介的白血球粘附的杂环化合物
CN1431999A (zh) 具有血管损伤活性的吲哚衍生物
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1518541A (zh) 苯基衍生物
CN1282316A (zh) 用作神经氨酸酶抑制剂的取代环戊烷和环戊烯化合物
CN1802159A (zh) 治疗哮喘及其它炎症或免疫性疾病的具有ccr3拮抗活性的2－苯氧基－和2－苯基磺酰胺衍生物
CN1717396A (zh) Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
CN1950343A (zh) 胺系碱性化合物及其用途
CN1910158A (zh) 含有氮杂环的β淀粉样蛋白生成的杂环磺酰胺抑制剂
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物
CN1443173A (zh) 作为TAFIa抑制剂的取代的咪唑
CN1131665A (zh) 哌嗪衍生物、含该类化合物的药物、其用途及制备方法
CN1479715A (zh) 用于抑制由白介素8诱导的中性粒细胞趋化作用的酰胺
CN1571786A (zh) 烷基醚衍生物或其盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee